EA202190168A1 - Усовершенствования в иммуногенных конъюгатах - Google Patents

Усовершенствования в иммуногенных конъюгатах

Info

Publication number
EA202190168A1
EA202190168A1 EA202190168A EA202190168A EA202190168A1 EA 202190168 A1 EA202190168 A1 EA 202190168A1 EA 202190168 A EA202190168 A EA 202190168A EA 202190168 A EA202190168 A EA 202190168A EA 202190168 A1 EA202190168 A1 EA 202190168A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunogenic conjugates
carrier polypeptide
saccharide antigen
amino acid
respect
Prior art date
Application number
EA202190168A
Other languages
English (en)
Inventor
Джеффери Фэйрман
Джон Хейнрикс
Вэй Чань
Original Assignee
Ваксайт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ваксайт, Инк. filed Critical Ваксайт, Инк.
Publication of EA202190168A1 publication Critical patent/EA202190168A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

В настоящей заявке описаны различные усовершенствования, касающиеся иммуногенных конъюгатов, содержащих полипептид-носитель и сахаридный антиген, причем сахаридный антиген ковалентно связан с полипептидом-носителем через остаток неприродной аминокислоты, содержащийся в нем.
EA202190168A 2018-07-04 2019-07-01 Усовершенствования в иммуногенных конъюгатах EA202190168A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693981P 2018-07-04 2018-07-04
PCT/US2019/040131 WO2020009993A1 (en) 2018-07-04 2019-07-01 Improvements in immunogenic conjugates

Publications (1)

Publication Number Publication Date
EA202190168A1 true EA202190168A1 (ru) 2021-06-07

Family

ID=67439412

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190168A EA202190168A1 (ru) 2018-07-04 2019-07-01 Усовершенствования в иммуногенных конъюгатах

Country Status (14)

Country Link
EP (1) EP3817775B1 (ru)
JP (2) JP7399934B2 (ru)
KR (1) KR20210042904A (ru)
CN (1) CN112543649A (ru)
AU (1) AU2019299836A1 (ru)
BR (1) BR112020026899A2 (ru)
CA (1) CA3105361A1 (ru)
DK (1) DK3817775T3 (ru)
EA (1) EA202190168A1 (ru)
IL (1) IL279855A (ru)
MX (1) MX2020014118A (ru)
PH (1) PH12020552282A1 (ru)
SG (1) SG11202012905PA (ru)
WO (1) WO2020009993A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
GB202108648D0 (en) * 2021-06-17 2021-08-04 Inst De Medicina Molecular Joaeo Lobo Antunes CRM197 protein carrier

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0375778B1 (en) 1987-06-19 1993-09-08 Terumo Kabushiki Kaisha Medical instrument and production thereof
AU634153B2 (en) 1988-02-01 1993-02-18 Wyeth Holdings Corporation T-cell epitope as carriers molecule for conjugate vaccines
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP2001190665A (ja) 2000-01-14 2001-07-17 Terumo Corp シリンジ
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0607026B1 (pt) 2005-04-08 2022-02-15 Wyeth Processos para redução do teor de proteína e preservação do teor de polissacarídeo capsular em um caldo de lisado celular de streptococcus pneumoniae complexo antes da purificação
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1967204B1 (en) * 2005-09-01 2013-10-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccination including serogroup c meningococcus
EP3020411A1 (en) * 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
AU2007307800C1 (en) 2006-10-10 2014-03-13 Wyeth Llc Purification of Streptococcus pneumoniae type 3 polysaccharides
MY150927A (en) 2007-03-23 2014-03-14 Wyeth Corp Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
US8609383B2 (en) * 2008-12-10 2013-12-17 The Scripps Research Institute Production of carrier-peptide conjugates using chemically reactive unnatural amino acids
EP2411045A1 (en) * 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
IT1398927B1 (it) * 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2011212183A (ja) 2010-03-31 2011-10-27 Terumo Corp プレフィルドシリンジ
CN105693865B (zh) * 2011-06-01 2020-07-17 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
US9493517B2 (en) * 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
JP6826367B2 (ja) * 2012-08-31 2021-02-03 ストロ バイオファーマ インコーポレーテッド アジド基を含む修飾アミノ酸
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN105263527A (zh) * 2012-12-27 2016-01-20 格林考瓦因有限公司 与crm197有关的方法和组合物
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
PL3055321T3 (pl) * 2013-10-11 2019-02-28 Sutro Biopharma, Inc. SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINY
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
AU2015208820B2 (en) * 2014-01-21 2020-05-14 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
KR102157200B1 (ko) * 2014-01-21 2020-09-21 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
PL3583947T3 (pl) * 2014-01-21 2024-04-02 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
JP2017510290A (ja) 2014-01-31 2017-04-13 フィナ バイオソリューションズ リミテッド ライアビリティ カンパニー Ｃｒｍ１９７および関連タンパク質の発現および精製
SG11201700673RA (en) * 2014-08-05 2017-02-27 Glaxosmithkline Biolog Sa Carrier molecule for antigens
WO2017173415A2 (en) * 2016-03-31 2017-10-05 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof
BR112019006278A2 (pt) * 2016-09-30 2019-07-02 Biological E Ltd composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína
CN118662649A (zh) * 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物

Also Published As

Publication number Publication date
KR20210042904A (ko) 2021-04-20
MX2020014118A (es) 2021-06-18
AU2019299836A1 (en) 2021-02-25
JP2021530468A (ja) 2021-11-11
JP7399934B2 (ja) 2023-12-18
PH12020552282A1 (en) 2021-06-28
WO2020009993A1 (en) 2020-01-09
BR112020026899A2 (pt) 2021-03-30
DK3817775T3 (da) 2024-09-16
JP2024037805A (ja) 2024-03-19
CN112543649A (zh) 2021-03-23
EP3817775A1 (en) 2021-05-12
CA3105361A1 (en) 2020-01-09
SG11202012905PA (en) 2021-01-28
EP3817775B1 (en) 2024-09-04
IL279855A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CY1123555T1 (el) Συμπλοκο πρωτεϊνης ιντερλευκινης 15 και χρηση αυτου
MX2024008677A (es) Conjugados de camptotecina.
CY1121870T1 (el) Anti-egfrviii αντισωματα και χρησεις αυτων
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
PE20181923A1 (es) Neoantigenos y metodos de su uso
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
PE20181399A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
IN2015DN02913A (ru)
NZ739721A (en) Antigen binding constructs to target molecules
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EA201690333A1 (ru) МОДУЛОКИНЫ НА ОСНОВЕ ДОМЕНА SUSHI IL-15 И IL-15Rα
PE20141151A1 (es) Proteinas de union al antigeno cd27l
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
EA201600190A1 (ru) Анти-prlr антитела и их применение
CY1114855T1 (el) Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
EP4257186A3 (en) Affinity medicant conjugates
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
EA202090889A1 (ru) Травяные композиции с улучшенной биодоступностью
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.